Alexa Fluor® 568 Anti-YB1 antibody [EPR22682-21],Abcam,AB312413
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Host
Rabbit
Reactivity
Human, Mouse
Application
Target Binding Affinity, Flow Cyt (Intra), IHC-P, Antibody Labelling, ICC/IF
Conjugate
Alexa Fluor® 568
Platform ID
BAB923436062

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data DNA- and RNA-binding protein involved in various processes, such as translational repression, RNA stabilization, mRNA splicing, DNA repair and transcription regulation (PubMed : 10817758, PubMed : 11698476, PubMed : 14718551, PubMed : 18809583, PubMed : 31358969, PubMed : 8188694). Predominantly acts as a RNA-binding protein : binds preferentially to the 5'-[CU]CUGCG-3' RNA motif and specifically recognizes mRNA transcripts modified by C5-methylcytosine (m5C) (PubMed : 19561594, PubMed : 31358969). Promotes mRNA stabilization : acts by binding to m5C-containing mRNAs and recruiting the mRNA stability maintainer ELAVL1, thereby preventing mRNA decay (PubMed : 10817758, PubMed : 11698476, PubMed : 31358969). Component of the CRD-mediated complex that promotes MYC mRNA stability (PubMed : 19029303). Contributes to the regulation of translation by modulating the interaction between the mRNA and eukaryotic initiation factors (By similarity). Plays a key role in RNA composition of extracellular exosomes by defining the sorting of small non-coding RNAs, such as tRNAs, Y RNAs, Vault RNAs and miRNAs (PubMed : 27559612, PubMed : 29073095). Probably sorts RNAs in exosomes by recognizing and binding C5-methylcytosine (m5C)-containing RNAs (PubMed : 28341602, PubMed : 29073095). Acts as a key effector of epidermal progenitors by preventing epidermal progenitor senescence : acts by regulating the translation of a senescence-associated subset of cytokine mRNAs, possibly by binding to m5C-containing mRNAs (PubMed : 29712925). Also involved in pre-mRNA alternative splicing regulation : binds to splice sites in pre-mRNA and regulates splice site selection (PubMed : 12604611). Binds to TSC22D1 transcripts, thereby inhibiting their translation and negatively regulating TGF-beta-mediated transcription of COL1A2 (By similarity). Also able to bind DNA : regulates transcription of the multidrug resistance gene MDR1 is enhanced in presence of the APEX1 acetylated form at 'Lys-6' and 'Lys-7' (PubMed : 18809583). Binds to promoters that contain a Y-box (5'-CTGATTGGCCAA-3'), such as MDR1 and HLA class II genes (PubMed : 18809583, PubMed : 8188694). Promotes separation of DNA strands that contain mismatches or are modified by cisplatin (PubMed : 14718551). Has endonucleolytic activity and can introduce nicks or breaks into double-stranded DNA, suggesting a role in DNA repair (PubMed : 14718551). The secreted form acts as an extracellular mitogen and stimulates cell migration and proliferation (PubMed : 19483673). See full target information YBX1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.
